Socialize with fellow attendees over breakfast to kick off the event. Complimentary headshots from a professional photographer to update your professional profile will be available.
The Editor-in-Chief of the Journal of Clinical Pathways (JCP) Winston Wong, PharmD will review the Journal’s most important articles from the past year. JCP features peer-reviewed education on the development, implementation, and evaluation of clinical pathways. Relevant topics include comparative-effectiveness research; big data analytics; methods in clinical pathway development; optimization of clinical pathway implementation and adherence; health economics and outcomes research; patient-centered outcomes; and alternative payment and value-based care models.
Bringing together the best of pathways and oncology business expertise. Lee Blansett will present critical trends from the IDN, Community Oncology, Payer and Pathways Reports that are driving the current oncology marketplace. Following his presentation, a panel of pathways and oncology business leaders will highlight their key takeaways and discuss where we will dive deeper throughout the event.
Review the latest developments from Capitol Hill and HHS and show how recent changes will affect community oncology practice.
Dr. Ray Page will discuss the intersection of personalized medicine and treatment pathways and how they can combine to drive the best outcomes in patients. Dr. Mary Cooley and Dr. David Lobach will present their work on a clinical decision-support tools for the management of uncontrolled cancer symptoms.
After completing this activity, learners will be able to • Assess efficacy and safety of current and recently approved agents to incorporate into second- and third-line treatment of HER2-positive breast cancer • Describe the challenges of creating and implementing clinical pathways for HER2-positive breast cancer • Develop clinical pathways for HER2-positive breast cancer to optimize evidence-based and cost effective second- and third- line treatments
Dr. Dennis Holmes will connect delays between diagnosis and treatment to their effects on patient outcomes. Then he will explore ways to close the diagnosis-treatment gap, including effective use of pathways.
Our keynote opening will provide insights into today’s top market dynamics impacting cancer care and the key trends to keep your eye on in the future. • Learn why self-insured employers are increasingly focused on improving their cancer care benefits and the impact on other stakeholders across the industry • Understand the complexities of the Medicare Advantage market and what its growth means for practice leaders and physicians leading the way, and their motivations
• Overview of the current consolidation of the healthcare industry, the major players and disruptors leading the way, and their motivations • Learn how leading providers are developing strategies to respond, including affiliation models
• Learn about the current status of home-based cancer care • Consider the evolving business case, including the current value proposition, service limitations, and potential future opportunities
• Understand the use case for AI in cancer care today, and study existing uses in oncology operations and care • Learn key principles for evaluating vendors and the legitimacy of AI-enabled technologies • Envision the future and how AI may significantly impact the delivery of care, including clinical pathways
• The current state of clinical research in community oncology • Increasing the reach and access of clinical trials into the community • How technologies and new models are changing clinical research
As genetics takes a greater role in the treatment of a wide spectrum of cancers, this session will examine genomic testing’s role in comprehensive oncology pathways.
Precision medicine has revolutionized cancer care, but ensuring widespread access and high-quality implementation across the care continuum remains a challenge. In this session, we will explore strategies to scale precision medicine expertise, addressing barriers and highlighting resources to deliver personalized care to all patients.
Join an in-depth case study of how using real-world evidence improves clinical pathways, streamlines clinical operations, and benefits patient outcomes.
An in-depth panel will investigate factors beyond drug costs that affect the bottom line and how pathways can effectively aid to manage these costs.
A presentation on the use of clinical pathways in the real world.
Join the Clinical Pathways Steering Committee as they gather to answer your outstanding questions from the previous three days of presentations.